Comparison of Multiparametric and Biparametric MRI in First Round Cognitive Targeted Prostate Biopsy in Patients with PSA Levels under 10 ng/mL

To determine the efficacy of cognitive targeted prostate biopsy using biparametric magnetic resonance imaging (b-MRI) for patients with prostate-specific antigen levels under 10 ng/mL. We reviewed data from 123 consecutive patients who underwent cognitive targeted prostate biopsy using prostate MRI....

Full description

Saved in:
Bibliographic Details
Published inYonsei medical journal Vol. 58; no. 5; pp. 994 - 999
Main Authors Lee, Dong Hoon, Nam, Jong Kil, Lee, Seung Soo, Han, Ji-Yeon, Lee, Joon Woo, Chung, Moon Kee, Park, Sung Woo
Format Journal Article
LanguageEnglish
Published Korea (South) Yonsei University College of Medicine 01.09.2017
연세대학교의과대학
Subjects
Online AccessGet full text
ISSN0513-5796
1976-2437
1976-2437
DOI10.3349/ymj.2017.58.5.994

Cover

Loading…
Abstract To determine the efficacy of cognitive targeted prostate biopsy using biparametric magnetic resonance imaging (b-MRI) for patients with prostate-specific antigen levels under 10 ng/mL. We reviewed data from 123 consecutive patients who underwent cognitive targeted prostate biopsy using prostate MRI. Of these patients, the first 55 underwent prostate biopsy using multiparametric MRI (mp-MRI), and the remaining 68 underwent prostate biopsy using b-MRI. For b-MRI, we generated T2 weighted axial imaging and diffusion-weighted imaging sequences. We found that 62 of the 123 men had suspicious lesions on MRI (32 of the 55 men in the mp-MRI group and 30 of the 68 men in the b-MRI group). We compared the prostate cancer detection rates and the proportions of clinically significant prostate cancer between the different MRI sequences. Between the two MRI groups, there were no statistically significant differences in prostate cancer detection rate and proportions of clinically significant prostate cancer (41.8% vs. 30.9%, p=0.208 and 82.6% vs. 76.2%, p=0.598). Among the 62 men who had suspicious lesions on MRI, the prostate cancer detection rates were 62.5% and 63.3% (p=0.709) in the mp-MRI and b-MRI groups, respectively, and the proportions of clinically significant prostate cancer were 95.0% and 84.2% (p=0.267). Prostate biopsy using b-MRI showed similar performance to that using mp-MRI for detecting prostate cancer and clinically significant prostate cancer. Considering the satisfactory performance and cost effectiveness of b-MRI, this technique could be a good option for obtaining intraprostatic information for first round prostate biopsy.
AbstractList To determine the efficacy of cognitive targeted prostate biopsy using biparametric magnetic resonance imaging (b-MRI) for patients with prostate-specific antigen levels under 10 ng/mL.PURPOSETo determine the efficacy of cognitive targeted prostate biopsy using biparametric magnetic resonance imaging (b-MRI) for patients with prostate-specific antigen levels under 10 ng/mL.We reviewed data from 123 consecutive patients who underwent cognitive targeted prostate biopsy using prostate MRI. Of these patients, the first 55 underwent prostate biopsy using multiparametric MRI (mp-MRI), and the remaining 68 underwent prostate biopsy using b-MRI. For b-MRI, we generated T2 weighted axial imaging and diffusion-weighted imaging sequences. We found that 62 of the 123 men had suspicious lesions on MRI (32 of the 55 men in the mp-MRI group and 30 of the 68 men in the b-MRI group). We compared the prostate cancer detection rates and the proportions of clinically significant prostate cancer between the different MRI sequences.MATERIALS AND METHODSWe reviewed data from 123 consecutive patients who underwent cognitive targeted prostate biopsy using prostate MRI. Of these patients, the first 55 underwent prostate biopsy using multiparametric MRI (mp-MRI), and the remaining 68 underwent prostate biopsy using b-MRI. For b-MRI, we generated T2 weighted axial imaging and diffusion-weighted imaging sequences. We found that 62 of the 123 men had suspicious lesions on MRI (32 of the 55 men in the mp-MRI group and 30 of the 68 men in the b-MRI group). We compared the prostate cancer detection rates and the proportions of clinically significant prostate cancer between the different MRI sequences.Between the two MRI groups, there were no statistically significant differences in prostate cancer detection rate and proportions of clinically significant prostate cancer (41.8% vs. 30.9%, p=0.208 and 82.6% vs. 76.2%, p=0.598). Among the 62 men who had suspicious lesions on MRI, the prostate cancer detection rates were 62.5% and 63.3% (p=0.709) in the mp-MRI and b-MRI groups, respectively, and the proportions of clinically significant prostate cancer were 95.0% and 84.2% (p=0.267).RESULTSBetween the two MRI groups, there were no statistically significant differences in prostate cancer detection rate and proportions of clinically significant prostate cancer (41.8% vs. 30.9%, p=0.208 and 82.6% vs. 76.2%, p=0.598). Among the 62 men who had suspicious lesions on MRI, the prostate cancer detection rates were 62.5% and 63.3% (p=0.709) in the mp-MRI and b-MRI groups, respectively, and the proportions of clinically significant prostate cancer were 95.0% and 84.2% (p=0.267).Prostate biopsy using b-MRI showed similar performance to that using mp-MRI for detecting prostate cancer and clinically significant prostate cancer. Considering the satisfactory performance and cost effectiveness of b-MRI, this technique could be a good option for obtaining intraprostatic information for first round prostate biopsy.CONCLUSIONProstate biopsy using b-MRI showed similar performance to that using mp-MRI for detecting prostate cancer and clinically significant prostate cancer. Considering the satisfactory performance and cost effectiveness of b-MRI, this technique could be a good option for obtaining intraprostatic information for first round prostate biopsy.
Purpose: To determine the efficacy of cognitive targeted prostate biopsy using biparametric magnetic resonance imaging (b-MRI) for patients with prostate-specific antigen levels under 10 ng/mL. Materials and Methods: We reviewed data from 123 consecutive patients who underwent cognitive targeted prostate biopsy usingprostate MRI. Of these patients, the first 55 underwent prostate biopsy using multiparametric MRI (mp-MRI), and the remaining68 underwent prostate biopsy using b-MRI. For b-MRI, we generated T2 weighted axial imaging and diffusion-weighted imaging sequences. We found that 62 of the 123 men had suspicious lesions on MRI (32 of the 55 men in the mp-MRI group and 30 of the 68 men in the b-MRI group). We compared the prostate cancer detection rates and the proportions of clinically significantprostate cancer between the different MRI sequences. Results: Between the two MRI groups, there were no statistically significant differences in prostate cancer detection rate and proportionsof clinically significant prostate cancer (41.8% vs. 30.9%, p=0.208 and 82.6% vs. 76.2%, p=0.598). Among the 62 men who had suspicious lesions on MRI, the prostate cancer detection rates were 62.5% and 63.3% (p=0.709) in the mp-MRI and b-MRI groups, respectively, and the proportions of clinically significant prostate cancer were 95.0% and 84.2% (p=0.267). Conclusion: Prostate biopsy using b-MRI showed similar performance to that using mp-MRI for detecting prostate cancer and clinically significant prostate cancer. Considering the satisfactory performance and cost effectiveness of b-MRI, this technique could be a good option for obtaining intraprostatic information for first round prostate biopsy. KCI Citation Count: 3
To determine the efficacy of cognitive targeted prostate biopsy using biparametric magnetic resonance imaging (b-MRI) for patients with prostate-specific antigen levels under 10 ng/mL. We reviewed data from 123 consecutive patients who underwent cognitive targeted prostate biopsy using prostate MRI. Of these patients, the first 55 underwent prostate biopsy using multiparametric MRI (mp-MRI), and the remaining 68 underwent prostate biopsy using b-MRI. For b-MRI, we generated T2 weighted axial imaging and diffusion-weighted imaging sequences. We found that 62 of the 123 men had suspicious lesions on MRI (32 of the 55 men in the mp-MRI group and 30 of the 68 men in the b-MRI group). We compared the prostate cancer detection rates and the proportions of clinically significant prostate cancer between the different MRI sequences. Between the two MRI groups, there were no statistically significant differences in prostate cancer detection rate and proportions of clinically significant prostate cancer (41.8% vs. 30.9%, p=0.208 and 82.6% vs. 76.2%, p=0.598). Among the 62 men who had suspicious lesions on MRI, the prostate cancer detection rates were 62.5% and 63.3% (p=0.709) in the mp-MRI and b-MRI groups, respectively, and the proportions of clinically significant prostate cancer were 95.0% and 84.2% (p=0.267). Prostate biopsy using b-MRI showed similar performance to that using mp-MRI for detecting prostate cancer and clinically significant prostate cancer. Considering the satisfactory performance and cost effectiveness of b-MRI, this technique could be a good option for obtaining intraprostatic information for first round prostate biopsy.
Author Lee, Dong Hoon
Lee, Seung Soo
Han, Ji-Yeon
Nam, Jong Kil
Lee, Joon Woo
Chung, Moon Kee
Park, Sung Woo
AuthorAffiliation 1 Department of Urology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea
2 Department of Radiology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea
AuthorAffiliation_xml – name: 2 Department of Radiology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea
– name: 1 Department of Urology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea
Author_xml – sequence: 1
  givenname: Dong Hoon
  surname: Lee
  fullname: Lee, Dong Hoon
  organization: Department of Urology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea
– sequence: 2
  givenname: Jong Kil
  surname: Nam
  fullname: Nam, Jong Kil
  organization: Department of Urology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea
– sequence: 3
  givenname: Seung Soo
  surname: Lee
  fullname: Lee, Seung Soo
  organization: Department of Urology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea
– sequence: 4
  givenname: Ji-Yeon
  surname: Han
  fullname: Han, Ji-Yeon
  organization: Department of Urology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea
– sequence: 5
  givenname: Joon Woo
  surname: Lee
  fullname: Lee, Joon Woo
  organization: Department of Radiology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea
– sequence: 6
  givenname: Moon Kee
  surname: Chung
  fullname: Chung, Moon Kee
  organization: Department of Urology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea
– sequence: 7
  givenname: Sung Woo
  surname: Park
  fullname: Park, Sung Woo
  organization: Department of Urology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28792144$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002251842$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp1UstuEzEUtVARTQsfwAZ5CYtM_RyPN0ghohApFVEIa8uZeFK3M3Zqe4LyFf3lepoWFSRWV_Y9D_n4nIET550B4D1GBaVMXhy6m4IgLApeFbyQkr0CIyxFOSaMihMwQhzTMReyPAVnMd4gRARG5A04JZWQBDM2AvdT3-10sNE76Bt41bfJ5rPuTAq2htpt4JeXF1fLGbQOXtoQE1z6Pu-nfutssnsDVzpsTTIbuAg-Jp1M5vpdPAyMhU7WuBThb5uu4eLnBM7N3rQRZgkTIEbQbS-6-VvwutFtNO-e5jn4dfl1Nf0-nv_4NptO5uOaUZrGZblmtakwFmwtEOaSUiooqhjSnOIGG0FLJGq6kZhqxnTJCEO1lGaNNdUNpufg01HXhUbd1lZ5bR_n1qvboCbL1UwNKTJSZuznI3bXrzuzqfMzgm7VLthOh8Mj8--Ns9dZZ68456TkPAt8fBII_q43ManOxtq0rXbG91FhSQSXrBQyQz-89Ppj8vxjGSCOgDpnHINpVG1z1NYP1rZVGKmhGyp3Qw3dULxSXOVuZCb-h_ks_n_OAyxVvU4
CitedBy_id crossref_primary_10_1016_j_esmoop_2022_100518
crossref_primary_10_1259_bjr_20190929
crossref_primary_10_1111_iju_15545
crossref_primary_10_3390_diagnostics12040799
crossref_primary_10_1177_17562872221096377
crossref_primary_10_1002_14651858_CD012663_pub2
crossref_primary_10_1038_s41391_019_0158_x
crossref_primary_10_7759_cureus_59470
crossref_primary_10_5534_wjmh_190079
crossref_primary_10_1016_j_euo_2020_02_005
crossref_primary_10_3390_life12060804
crossref_primary_10_2214_AJR_20_23219
crossref_primary_10_3349_ymj_2019_60_4_346
crossref_primary_10_1007_s12254_018_0458_1
Cites_doi 10.1148/radiol.09090475
10.1016/j.eururo.2012.02.002
10.1016/j.eururo.2013.05.059
10.1007/s00330-008-1190-8
10.1007/s00234-016-1658-1
10.1111/j.1464-410X.2012.11646.x
10.1002/cncr.28216
10.1016/j.urology.2015.09.035
10.1097/RLI.0b013e318263f0fd
10.1093/jjco/hyt041
10.1016/j.eururo.2015.08.052
10.1016/j.eururo.2013.12.012
10.1016/j.juro.2010.10.076
10.3349/ymj.2016.57.3.565
10.1016/j.juro.2013.05.052
10.1093/jnci/djp001
10.1111/j.1464-410X.2010.09808.x
10.1111/bju.12639
10.1093/jnci/djq099
ContentType Journal Article
Copyright Copyright: Yonsei University College of Medicine 2017
Copyright: Yonsei University College of Medicine 2017 2017
Copyright_xml – notice: Copyright: Yonsei University College of Medicine 2017
– notice: Copyright: Yonsei University College of Medicine 2017 2017
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ACYCR
DOI 10.3349/ymj.2017.58.5.994
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1976-2437
EndPage 999
ExternalDocumentID oai_kci_go_kr_ARTI_2437426
PMC5552655
28792144
10_3349_ymj_2017_58_5_994
Genre Journal Article
Comparative Study
GrantInformation_xml – fundername: ;
  grantid: 30-2015-027
GroupedDBID ---
.55
.GJ
123
29R
2WC
36B
5-W
53G
5RE
8JR
8XY
9ZL
AAYXX
ACYCR
ADBBV
ADRAZ
AEGXH
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
CS3
DIK
DU5
E3Z
EBD
EF.
EMB
EMOBN
F5P
GROUPED_DOAJ
GX1
HYE
KQ8
L7B
M48
MK0
O5R
O5S
OK1
OVT
P2P
PGMZT
RNS
RPM
SV3
TR2
X7M
XSB
ZGI
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
M~E
ID FETCH-LOGICAL-c433t-66b4ce81174b70159333730840a531f1e73607c3d913a44a64240c99eb1a3af13
IEDL.DBID M48
ISSN 0513-5796
1976-2437
IngestDate Tue Nov 21 21:47:45 EST 2023
Thu Aug 21 13:18:09 EDT 2025
Fri Jul 11 02:23:41 EDT 2025
Mon Jul 21 05:59:52 EDT 2025
Tue Jul 01 04:03:08 EDT 2025
Thu Apr 24 22:51:47 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords prostate biopsy
Prostate cancer
magnetic resonance imaging
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c433t-66b4ce81174b70159333730840a531f1e73607c3d913a44a64240c99eb1a3af13
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
https://www.eymj.org/DOIx.php?id=10.3349/ymj.2017.58.5.994
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3349/ymj.2017.58.5.994
PMID 28792144
PQID 1927594679
PQPubID 23479
PageCount 6
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_2437426
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5552655
proquest_miscellaneous_1927594679
pubmed_primary_28792144
crossref_citationtrail_10_3349_ymj_2017_58_5_994
crossref_primary_10_3349_ymj_2017_58_5_994
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-09-01
PublicationDateYYYYMMDD 2017-09-01
PublicationDate_xml – month: 09
  year: 2017
  text: 2017-09-01
  day: 01
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Yonsei medical journal
PublicationTitleAlternate Yonsei Med J
PublicationYear 2017
Publisher Yonsei University College of Medicine
연세대학교의과대학
Publisher_xml – name: Yonsei University College of Medicine
– name: 연세대학교의과대학
References Draisma (10.3349/ymj.2017.58.5.994_ref1) 2009; 101
de Rooij (10.3349/ymj.2017.58.5.994_ref19) 2014; 66
Yerram (10.3349/ymj.2017.58.5.994_ref10) 2012; 110
Lee (10.3349/ymj.2017.58.5.994_ref8) 2016; 57
Welch (10.3349/ymj.2017.58.5.994_ref2) 2010; 102
Stojanov (10.3349/ymj.2017.58.5.994_ref13) 2016; 58
Lee (10.3349/ymj.2017.58.5.994_ref3) 2013; 43
Selnæs (10.3349/ymj.2017.58.5.994_ref5) 2012; 47
Cheikh (10.3349/ymj.2017.58.5.994_ref16) 2009; 19
Turkbey (10.3349/ymj.2017.58.5.994_ref6) 2010; 255
Rastinehad (10.3349/ymj.2017.58.5.994_ref9) 2011; 185
Delongchamps (10.3349/ymj.2017.58.5.994_ref17) 2011; 107
Weinreb (10.3349/ymj.2017.58.5.994_ref18) 2016; 69
Rais-Bahrami (10.3349/ymj.2017.58.5.994_ref12) 2013; 190
Fascelli (10.3349/ymj.2017.58.5.994_ref15) 2016; 88
Siddiqui (10.3349/ymj.2017.58.5.994_ref7) 2013; 64
Rais-Bahrami (10.3349/ymj.2017.58.5.994_ref14) 2015; 115
Stamatakis (10.3349/ymj.2017.58.5.994_ref11) 2013; 119
Bul (10.3349/ymj.2017.58.5.994_ref4) 2012; 62
18925403 - Eur Radiol. 2009 Mar;19(3):770-8
26427566 - Eur Urol. 2016 Jan;69(1):16-40
23821585 - Cancer. 2013 Sep 15;119(18):3359-66
24377803 - Eur Urol. 2014 Sep;66(3):430-6
24447678 - BJU Int. 2015 Mar;115(3):381-8
23580758 - Jpn J Clin Oncol. 2013 May;43(5):553-8
26680244 - Urology. 2016 Feb;88:125-34
23130821 - BJU Int. 2012 Dec;110(11 Pt B):E783-8
20413742 - J Natl Cancer Inst. 2010 May 5;102(9):605-13
26873830 - Neuroradiology. 2016 May;58(5):433-41
26996553 - Yonsei Med J. 2016 May;57(3):565-71
21239006 - J Urol. 2011 Mar;185(3):815-20
19276453 - J Natl Cancer Inst. 2009 Mar 18;101(6):374-83
23727310 - J Urol. 2013 Nov;190(5):1721-1727
21044250 - BJU Int. 2011 May;107(9):1411-8
20308447 - Radiology. 2010 Apr;255(1):89-99
23787357 - Eur Urol. 2013 Nov;64(5):713-719
23011187 - Invest Radiol. 2012 Nov;47(11):624-33
22342775 - Eur Urol. 2012 Aug;62(2):195-200
References_xml – volume: 255
  start-page: 89
  year: 2010
  ident: 10.3349/ymj.2017.58.5.994_ref6
  publication-title: Radiology
  doi: 10.1148/radiol.09090475
– volume: 62
  start-page: 195
  year: 2012
  ident: 10.3349/ymj.2017.58.5.994_ref4
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2012.02.002
– volume: 64
  start-page: 713
  year: 2013
  ident: 10.3349/ymj.2017.58.5.994_ref7
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2013.05.059
– volume: 19
  start-page: 770
  year: 2009
  ident: 10.3349/ymj.2017.58.5.994_ref16
  publication-title: Eur Radiol
  doi: 10.1007/s00330-008-1190-8
– volume: 58
  start-page: 433
  year: 2016
  ident: 10.3349/ymj.2017.58.5.994_ref13
  publication-title: Neuroradiology
  doi: 10.1007/s00234-016-1658-1
– volume: 110
  start-page: E783
  issue: 11 Pt B
  year: 2012
  ident: 10.3349/ymj.2017.58.5.994_ref10
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2012.11646.x
– volume: 119
  start-page: 3359
  year: 2013
  ident: 10.3349/ymj.2017.58.5.994_ref11
  publication-title: Cancer
  doi: 10.1002/cncr.28216
– volume: 88
  start-page: 125
  year: 2016
  ident: 10.3349/ymj.2017.58.5.994_ref15
  publication-title: Urology
  doi: 10.1016/j.urology.2015.09.035
– volume: 47
  start-page: 624
  year: 2012
  ident: 10.3349/ymj.2017.58.5.994_ref5
  publication-title: Invest Radiol
  doi: 10.1097/RLI.0b013e318263f0fd
– volume: 43
  start-page: 553
  year: 2013
  ident: 10.3349/ymj.2017.58.5.994_ref3
  publication-title: Jpn J Clin Oncol
  doi: 10.1093/jjco/hyt041
– volume: 69
  start-page: 16
  year: 2016
  ident: 10.3349/ymj.2017.58.5.994_ref18
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2015.08.052
– volume: 66
  start-page: 430
  year: 2014
  ident: 10.3349/ymj.2017.58.5.994_ref19
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2013.12.012
– volume: 185
  start-page: 815
  year: 2011
  ident: 10.3349/ymj.2017.58.5.994_ref9
  publication-title: J Urol
  doi: 10.1016/j.juro.2010.10.076
– volume: 57
  start-page: 565
  year: 2016
  ident: 10.3349/ymj.2017.58.5.994_ref8
  publication-title: Yonsei Med J
  doi: 10.3349/ymj.2016.57.3.565
– volume: 190
  start-page: 1721
  year: 2013
  ident: 10.3349/ymj.2017.58.5.994_ref12
  publication-title: J Urol
  doi: 10.1016/j.juro.2013.05.052
– volume: 101
  start-page: 374
  year: 2009
  ident: 10.3349/ymj.2017.58.5.994_ref1
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djp001
– volume: 107
  start-page: 1411
  year: 2011
  ident: 10.3349/ymj.2017.58.5.994_ref17
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2010.09808.x
– volume: 115
  start-page: 381
  year: 2015
  ident: 10.3349/ymj.2017.58.5.994_ref14
  publication-title: BJU Int
  doi: 10.1111/bju.12639
– volume: 102
  start-page: 605
  year: 2010
  ident: 10.3349/ymj.2017.58.5.994_ref2
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djq099
– reference: 21239006 - J Urol. 2011 Mar;185(3):815-20
– reference: 23821585 - Cancer. 2013 Sep 15;119(18):3359-66
– reference: 26873830 - Neuroradiology. 2016 May;58(5):433-41
– reference: 21044250 - BJU Int. 2011 May;107(9):1411-8
– reference: 19276453 - J Natl Cancer Inst. 2009 Mar 18;101(6):374-83
– reference: 24447678 - BJU Int. 2015 Mar;115(3):381-8
– reference: 23580758 - Jpn J Clin Oncol. 2013 May;43(5):553-8
– reference: 23130821 - BJU Int. 2012 Dec;110(11 Pt B):E783-8
– reference: 24377803 - Eur Urol. 2014 Sep;66(3):430-6
– reference: 20308447 - Radiology. 2010 Apr;255(1):89-99
– reference: 23787357 - Eur Urol. 2013 Nov;64(5):713-719
– reference: 26427566 - Eur Urol. 2016 Jan;69(1):16-40
– reference: 26680244 - Urology. 2016 Feb;88:125-34
– reference: 26996553 - Yonsei Med J. 2016 May;57(3):565-71
– reference: 23727310 - J Urol. 2013 Nov;190(5):1721-1727
– reference: 20413742 - J Natl Cancer Inst. 2010 May 5;102(9):605-13
– reference: 18925403 - Eur Radiol. 2009 Mar;19(3):770-8
– reference: 23011187 - Invest Radiol. 2012 Nov;47(11):624-33
– reference: 22342775 - Eur Urol. 2012 Aug;62(2):195-200
SSID ssj0027102
Score 2.2353463
SecondaryResourceType review_article
Snippet To determine the efficacy of cognitive targeted prostate biopsy using biparametric magnetic resonance imaging (b-MRI) for patients with prostate-specific...
Purpose: To determine the efficacy of cognitive targeted prostate biopsy using biparametric magnetic resonance imaging (b-MRI) for patients with...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 994
SubjectTerms Biopsy
Cognition
Humans
Image-Guided Biopsy
Magnetic Resonance Imaging - methods
Male
Middle Aged
Original
Prostate - pathology
Prostate-Specific Antigen - metabolism
Prostatectomy
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - diagnostic imaging
Prostatic Neoplasms - pathology
Treatment Outcome
의학일반
Title Comparison of Multiparametric and Biparametric MRI in First Round Cognitive Targeted Prostate Biopsy in Patients with PSA Levels under 10 ng/mL
URI https://www.ncbi.nlm.nih.gov/pubmed/28792144
https://www.proquest.com/docview/1927594679
https://pubmed.ncbi.nlm.nih.gov/PMC5552655
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002251842
Volume 58
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Yonsei Medical Journal, 2017, 58(5), , pp.994-999
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELfWISFeEN9kQGUQT0jpktiO4weERkW1oRVVYxV7s9zYGWVrsiWdRP8K_mXu8lFWVHiKlNix4jvn7mff_Y6Qt4rZILbM-CZykc-jWeDPEp74SWRlai0YiBCTk8df4sMp_3wmznZIV96qncBqK7TDelLT8nLw83r1ARb8e0ScjKv91eIHxmjJgUgGYqAU75E7YJhixGJjnvzBX2EQNQeb27shMXAiFZKIbVipXl5m2xzQv-Mobxmm0QNyv_Uo6UGjAg_Jjssfkbvj9sz8Mfk1XJcapEVG64xbJPxeYC2tlJrc0o-3b4xPjug8p6M5-IX0BKsu0WEXY0RP68BxZ-kEs0XAT4W-xVW1wh6ThqK1ori3SydfD-gxRiRVFPPUShoGND_fXxw_IdPRp9Phod-WYfBTztjSj-MZTx0mpPKZBO9BMcbgvwDI0IAks9BJFgcyZVaFzHBuANHwIFUKrIBhJgvZU7KbF7l7Tii3MmLWscwFBnCPVVmUcSlDZ6OQZTz1SNBNu05bjnIslXGpAaug0DQITaPQtEi00CA0j7xbd7lqCDr-1_gNyFJfpHONtNp4PS_0RakBPBxp5GYEh8UjrztRa1hreIBiclfcVBq8YSkUmBblkWeN6NdjdprjEbmhFOsGOODmk3z-vebzFgJrFIi9f77zBbmHn9GEtr0ku8vyxr0CX2g565Oe8L_1652Efq3tvwFpHAfX
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+Multiparametric+and+Biparametric+MRI+in+First+Round+Cognitive+Targeted+Prostate+Biopsy+in+Patients+with+PSA+Levels+under+10+ng%2FmL&rft.jtitle=Yonsei+medical+journal&rft.au=Lee%2C+Dong+Hoon&rft.au=Nam%2C+Jong+Kil&rft.au=Lee%2C+Seung+Soo&rft.au=Han%2C+Ji+Yeon&rft.date=2017-09-01&rft.eissn=1976-2437&rft.volume=58&rft.issue=5&rft.spage=994&rft_id=info:doi/10.3349%2Fymj.2017.58.5.994&rft_id=info%3Apmid%2F28792144&rft.externalDocID=28792144
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0513-5796&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0513-5796&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0513-5796&client=summon